A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This study has been completed.
Gynecologic Oncology Group
Information provided by:
National Cancer Institute (NCI)
First received: July 14, 2009
Last updated: August 8, 2012
Last verified: January 2010
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB. A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jun;125(3):635-9. doi: 10.1016/j.ygyno.2012.03.023. Epub 2012 Mar 22.